Ethinylestradiol/drospirenone

Drug Profile

Ethinylestradiol/drospirenone

Alternative Names: Dihydrospirorenone/ethinylestradiol; Drospirenone/ethinylestradiol; Petibelle; SH 470; Yasmin; ZK 30595

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Class Alkylated estrogenic steroids; Androstenes; Norpregnatrienes; Oral contraceptives; Progesterone congeners; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pregnancy
  • No development reported Acne; Premenstrual dysphoric disorder; Premenstrual syndrome

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 08 Sep 2015 Generic equivalent available in USA for Contraception
  • 09 Feb 2015 Launched for Contraception/Pregnancy (Prevention) in Switzerland, Norway, Israel, China, Malaysia, Philippines, Singapore, Thailand, Indonesia, Hong Kong and South Africa (PO) prior to February 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top